Harbor Investment Advisory LLC Has $271,000 Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Harbor Investment Advisory LLC increased its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 754.3% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 3,964 shares of the medical device company's stock after buying an additional 3,500 shares during the quarter. Harbor Investment Advisory LLC's holdings in DexCom were worth $271,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in DXCM. Geode Capital Management LLC grew its stake in shares of DexCom by 0.6% in the fourth quarter. Geode Capital Management LLC now owns 9,993,698 shares of the medical device company's stock worth $775,256,000 after acquiring an additional 56,094 shares in the last quarter. Norges Bank purchased a new position in DexCom during the 4th quarter worth $385,367,000. Northern Trust Corp lifted its position in DexCom by 22.2% in the fourth quarter. Northern Trust Corp now owns 4,146,249 shares of the medical device company's stock valued at $322,454,000 after purchasing an additional 753,857 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of DexCom by 3.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,825,206 shares of the medical device company's stock worth $219,716,000 after buying an additional 91,051 shares in the last quarter. Finally, Artisan Partners Limited Partnership lifted its stake in shares of DexCom by 12.2% in the fourth quarter. Artisan Partners Limited Partnership now owns 1,853,565 shares of the medical device company's stock valued at $144,152,000 after purchasing an additional 201,181 shares during the period. Hedge funds and other institutional investors own 97.75% of the company's stock.

Insider Buying and Selling at DexCom

In other DexCom news, COO Jacob Steven Leach sold 14,076 shares of the business's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $990,668.88. Following the sale, the chief operating officer now directly owns 313,497 shares in the company, valued at approximately $22,063,918.86. The trade was a 4.30% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Sadie Stern sold 6,184 shares of the business's stock in a transaction on Tuesday, May 27th. The stock was sold at an average price of $85.11, for a total value of $526,320.24. Following the completion of the sale, the executive vice president now directly owns 109,621 shares in the company, valued at $9,329,843.31. This represents a 5.34% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 83,110 shares of company stock worth $6,103,505 over the last ninety days. Company insiders own 0.32% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on DXCM shares. Morgan Stanley upped their target price on DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a report on Friday, February 14th. Wells Fargo & Company restated an "overweight" rating on shares of DexCom in a report on Saturday, March 8th. Robert W. Baird dropped their price target on DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a research note on Friday, May 2nd. Mizuho assumed coverage on shares of DexCom in a report on Thursday, April 10th. They set an "outperform" rating and a $85.00 target price on the stock. Finally, Citigroup restated a "buy" rating and set a $102.00 target price (up previously from $82.00) on shares of DexCom in a report on Thursday, May 22nd. Five research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $98.32.

DexCom Stock Performance

Shares of DXCM traded up $0.13 during mid-day trading on Thursday, hitting $85.74. The stock had a trading volume of 2,394,712 shares, compared to its average volume of 4,337,558. The company has a market cap of $33.62 billion, a PE ratio of 59.96, a PEG ratio of 2.30 and a beta of 1.43. The company's fifty day simple moving average is $75.64 and its two-hundred day simple moving average is $78.89. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $120.48.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). DexCom had a return on equity of 30.14% and a net margin of 14.29%. The business had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1.02 billion. During the same period last year, the company posted $0.32 earnings per share. The firm's revenue for the quarter was up 12.5% on a year-over-year basis. On average, equities analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.